Pharmaceutical Intermediates
- • Analgesics (59)
- • Anesthetics (52)
- • Anti-Addiction Agents (8)
- • Antibacterials (118)
- • Anticonvulsants (20)
- • Antidementia Agents (23)
- • Antidepressants (35)
- • Antiemetics (24)
- • Antifungals (24)
- • Antigout Agents (9)
- • Anti-inflammatory Agents (28)
- • Antimigraine Agents (21)
- • Antineoplastics (427)
- • Antiparasitics (11)
- • Antiparkinson Agents (28)
- • Antipsychotics (54)
- • Antispasticity Agents (12)
- • Antivirals (146)
- • Anxiolytics (16)
- • Blood Glucose Regulators (106)
- • Blood Products (61)
- • Cardiovascular Agents (179)
- • CNS Agents (22)
- • Dental and Oral Agents (8)
- • Dermatological Agents (19)
- • Electrolytes (15)
- • Gastrointestinal Agents (63)
- • Genetic/Enzyme Disorder (12)
- • Genitourinary Agents (47)
- • Immunological Agents (36)
- • Metabolic Bone Disease (6)
- • Ophthalmic Agents (476)
- • Respiratory Tract (51)
- • Skeletal Muscle Relaxants (5)
- • Sleep Disorder Agents (28)
- • Oled Material Intermediate (333)
- • Heterocyclic Compound (9764)
- • Bulk Drug Intermediates (17782)
Related News
-
Semaglutide initiates Phase III clinical trial of NASH in China
2021-07-28 -
Pharmactive promotes black garlic extract that beneficial to cardiovascular
2020-04-20 -
Aging of arteries is an important feature of cardiovascular diseases
2019-12-12 -
Crown Bioscience expands cardiovascular and metabolic diseaseresearch capability
2018-11-16
Cardiovascular Agents
Methanone, (5-amino-2-butyl-3-benzofuranyl)[4-[3-(dibutylamino)propoxy]phenyl]-, ethanedioate (1:2)
(500791-70-8)-
Pharmaceutical Grade / 99%
-
-
Industrial Grade / 99%
-
Request for quotation , get quotes from more suppliers.
-
- / 99.00%
-
Industrial Grade / 99.0%
-
-
Industrial Grade / 99%
Request for quotation , get quotes from more suppliers.
Methyl 2-[[(2′-cyano[1,1′-biphenyl]-4-yl)methyl]amino]-3-nitrobenzoate
(139481-28-0)-
Pharmaceutical Grade / 98%
-
Industrial Grade / 99.0%
-
-
Request for quotation , get quotes from more suppliers.
Methyl 2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinecarboxylate
(121659-86-7)-
- / 99.00%
-
Industrial Grade / 99.0%
-
-
Request for quotation , get quotes from more suppliers.
Methyl (3R,6E)-3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-5-oxo-6-heptenoate
(147118-38-5)-
Pharmaceutical Grade / 98.0%
-
Industrial Grade / 99.0%
-
-
Industrial Grade / 99%
Request for quotation , get quotes from more suppliers.
-
Industrial Grade / pharmaceutical grade / 99%
$1/MT EXW
-
- / 99.00%
-
-
- / 0.99%
Request for quotation , get quotes from more suppliers.
METHALLYLPHENYLSULFIDE
(702-00-1)-
Industrial Grade / 99%
-
-
-
Request for quotation , get quotes from more suppliers.
More Information
Cardiovascular agents are a varied group of medications used to remedy a range of heart and vascular diseases. These agents are classified according to their therapeutic action. High blood pressure antihypertensives are used, such as ACE inhibitors (enalapril) and beta-blockers (metoprolol) to reduce it. Warfarin and heparin ruling the world are anticoagulants, meaning they prevent the formation of blood clots, thereby reducing the probability of stroke and heart attacks. Coumarins, aspirins and clopidogrel are antiplatelet agents which prevent the formation of clots by inhibiting platelet aggregation. Furosemide is a diuretic to promotes the elimination of excess sodium and water, particularly in the case of controlling blood pressure. Statins like atorvastatin work as lipid-lowering agents to help reduce cholesterol levels as the risk of atherosclerosis is thereby minimized. Also, antiarrhythmics such as amiodarone control abnormal heart rhythms.
Applications of Cardiovascular Agents:
● Management of hypertension
● Prevention of thromboembolic events
● Treatment of angina pectoris
● Control of cardiac arrhythmias
● Reduction of cholesterol levels
● Alleviation of heart failure symptoms
Frequently Asked Questions
Cardiovascular agents are a class of pharmaceutical drugs used to treat conditions related to the heart and blood vessels. These include antihypertensives, antiarrhythmics, vasodilators, beta-blockers, calcium channel blockers, and lipid-lowering agents. They play a critical role in managing diseases such as hypertension, angina, heart failure, and arrhythmias by regulating blood pressure, heart rate, and cholesterol levels.
Cardiovascular agents work through various mechanisms depending on their drug class. For example, beta-blockers reduce heart rate and blood pressure by blocking adrenaline effects; ACE inhibitors relax blood vessels by inhibiting angiotensin-converting enzyme; and statins lower LDL cholesterol by inhibiting HMG-CoA reductase. Each type targets specific pathways to improve cardiovascular function and reduce the risk of complications like stroke or myocardial infarction.
Common side effects of cardiovascular medications may include dizziness, fatigue, headache, nausea, dry cough (especially with ACE inhibitors), swelling in the legs (with calcium channel blockers), and changes in heart rhythm. Some lipid-lowering agents like statins can cause muscle pain or elevated liver enzymes. Patients should always consult healthcare providers before starting or adjusting any cardiovascular therapy.
When sourcing cardiovascular APIs, consider suppliers that comply with international regulatory standards such as FDA, EMA, or WHO-GMP certifications. Evaluate their quality control systems, including documentation of impurity profiles, stability data, and batch consistency. Reliable suppliers also provide comprehensive regulatory support, including DMFs (Drug Master Files) and analytical method validation, ensuring smooth integration into final drug formulations.
Cardiovascular agents are essential in both acute and chronic care settings. They are widely used to manage hypertension, prevent recurrent heart attacks, control atrial fibrillation, treat heart failure symptoms, and reduce atherosclerosis risk through lipid management. In hospital environments, intravenous forms of these agents help stabilize patients during cardiac emergencies, while oral formulations support long-term disease control and improved patient outcomes.